Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models

Cancer Letters

Volumn 324, Issue 1, 2012, Pages 98-108

  Chiacchiera, Fulvio ^a   Grossi, Valentina ^a   Cappellari, Marianna ^a   Peserico, Alessia ^a   Simonatto, Marta ^b   Germani, Aldo ^a   Russo, Silvana ^c   Moyer, Mary P ^d   Resta, Nicoletta ^c   Murzilli, Stefania ^a   Simone, Cristiano ^a,c,e  

^a Santa Maria Imbaro   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d INCELL Corporation ^*  (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Animal models; Cell death; Colorectal cancer; ERK; P38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN BID; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MODEL; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BENZAMIDES; CASPASE 8; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIPHENYLAMINE; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HT29 CELLS; HUMANS; IMIDAZOLES; MALE; MAP KINASE KINASE 1; MICE; MICE, NUDE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 14; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84864071314     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.006     Document Type: Article

References (48)

1. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signaling. Biochem. J. 2010, 429:403-417.
2. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
3. Chiacchiera F., Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett. 2008, 265:16-26.
4. Dolado I., Swat A., Ajenjo N., De Vita G., Cuadrado A., Nebreda A.R. p38Alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11:191-205.
5. Hui L., Bakiri L., Mairhorfer A., Schweifer N., Haslinger C., Kenner L., et al. p38Alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 2007, 39:741-749.
6. Ventura J.J., Tenbaum S., Perdiguero E., Huth M., Guerra C., Barbacid M., et al. p38Alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat. Genet. 2007, 39:750-758.
7. Emerling B.M., Platanias L.C., Black E., Nebreda A.R., Davis R.J., Chandel N.S. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol. Cell Biol. 2005, 25:4853-4862.
8. Halawani D., Mondeh R., Stanton L.A., Beier F. P38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 2004, 23:3726-3731.
9. Adam A.P., George A., Schewe D., Bragado P., Iglesias B.V., Ranganathan A.C., et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 2009, 69:5664-5672.
10. Son J.K., Varadarajan S., Bratton S.B. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ. 2010, 17:1288-1301.
11. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 2002, 115:3193-3206.
12. Hsieh Y.H., T Wu T., Huang C.Y., Hsieh Y.S., Hwang J.M., Liu J.Y. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res. 2007, 67:4320-4327.
13. Junttila M.R., Ala-Aho R., Jokilehto T., Peltonen J., Kallajoki M., Grenman R., et al. p38Alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007, 26:5267-5279.
14. Kim M.S., Lee E.J., Kim H.R., Moon A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 2003, 63:5454-5461.
15. Comes F., Matrone A., Lastella P., Nico B., Susca F.C., Bagnulo R., et al. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 2007, 14:693-702.
16. Chiacchiera F., Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009, 5:1030-1033.
17. Chiacchiera F., Matrone A., Ferrari E., Ingravallo G., Lo Sasso G., Murzilli S., et al. p38Alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ. 2009, 16:1203-1214.
18. 3A axis as a target for cancer treatment. Cell Cycle 2010, 9:1091-1096.
19. Paillas S., Boissiere F., Bibeau F., Denouel A., Mollevi C., Causse A., et al. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 2011, 71:1041-1049.
20. Yang S.Y., Miah A., Sales K.M., Fuller B., Seifalian A.M., Winslet M. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. Int. J. Oncol. 2011, 38:1695-1702.
21. Fang J.Y., Richardson B.C. The MAPK signaling pathways and colorectal cancer. Lancet Oncol. 2005, 6:322-327.
22. Balmanno K., Cook S.J. Tumor cell survival signaling by the ERK1/2 pathway. Cell Death Differ. 2009, 16:368-377.
23. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5:810-816.
24. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., et al. Multicenter phase II study of the oral MEK inhibitor CI-1040 in patients with advanced non-small-cell lung breast colon and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
25. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
26. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
27. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
28. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
29. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
30. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
31. Desagher S., Osen-Sand A., Montessuit S., Magnenat E., Vilbois F., Hochmann A., Journot L., Antonsson B., Martinou J.C. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol. Cell 2001, 8:601-611.
32. Wang S., El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633.
33. De Robertis M., Massi E., Poeta M.L., Carotti S., Morini S., Cecchetelli L., et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog. 2011, 10:9.
34. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J Clin. 2011, 61:69-90.
35. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
36. Rustgi A.K. The genetics of hereditary colon cancer. Gene. Dev. 2007, 21:2525-2538.
37. Kinzler K.W., Vogelstein B B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
38. Segal N.H., Saltz L.B. Evolving treatment of advanced colon cancer. Ann. Rev. Med. 2009, 60:207-219.
39. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924-935.
40. Thompson N., Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 2005, 5:350-356.
41. Wickenden J.A., Jin H., Johnson M., Gillings A.S., Newson C., Austin M., et al. Colorectal cancer cells with the BRAF (V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 2008, 27:7150-7161.
42. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 2011, 464:427-430.
43. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
44. Pattingre S., Bauvy C., Codogno P. Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J. Biol. Chem. 2003, 278:16667-16674.
45. Wen H.C., Avivar-Valderas A., Sosa M.S., Girnius N., Farias E.F., Davis R.J., et al. p38α Signaling induces anoikis and lumen formation during mammary morphogenesis. Sci. Signal. 2011, 4:34.
46. Junttila M.R., Li S.P., Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. Faseb. J. 2008, 22:954-965.
47. Lee M.R., Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. 2005, 12:2979-2994.
48. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.